PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing

Award Notice Posted

Solicitation number
75N91024D00008
Agency
Awarded
to Curia Bio Inc.
Set-aside
No set-aside

Opportunity facts

Contract number
75N91024D00008 Federal IDV award
Place of performance
Belmont, California 94002, United States
Points of contact

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $149,995,000 IDIQ contract to CURIA BIO INC for the PREVENT Cancer Preclinical Drug Development Program. The contract provides preclinical efficacy and intermediate endpoint biomarkers, preclinical services for cGMP biopharmaceutical product development and manufacturing, and toxicology and pharmacology testing. The contract has the potential for fixed-price and cost plus fixed fee task orders.

Notice text

This is an IDIQ award (with potential fixed-price and cost plus fixed fee task orders) associated with the CGMP Pool under the PREVENT Preclinical Drug Development Program awarded competitively. 

Awarded contract 75N91024D00008 to CURIA BIO INC for 149995000.00 on 2024-09-13.

Notice history

Notice Type Posted
This notice Latest Award Notice
PREVENT Preclinical Efficacy & Endpoint Biomarkers Award Notice
PREVENT Preclinical Efficacy & Endpoint Biomarkers Award Notice
PREVENT Preclinical Efficacy & Endpoint Biomarkers Award Notice
Prevent IDIQ mato RFP Latest solicitation Solicitation
Prevent IDIQ mato RFP Original Pre-Solicitation

6 of 13 notices listed here. See the rest on GovTribe.

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login

GovTribe for Federal Contractors